Machine learning for Acute Myeloid Leukemia (ALM)

To conduct scientific research and further our dedication to providing best-in-class technical expertise that improves benefit-risk profile of treatments for patients diagnosed with ALM. Using real-world publicly available clinical trial datasets, we developed principal component algorithms to measure and accelerate treatment response insights for patients living with ALM. Olu developed principal component algorithms to measure and accelerate gene expression insights for patients living with AML. The aim is to help identify more effective treatments for patients through accelerated gene expression insights for an estimated 21,000 people of all ages diagnosed with AML.